E64d, a CTSB inhibitor [58], and MDL28170, a CTSL inhibitor, both showed therapeutic antiviral effects targeting SARS-CoV-2 entry [59] and are excellent candidates against SARS-CoV-2 omicron infections. This evidence concerns the gene CTSB and infection.